Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara-VCD Induction Followed by ASCT or Dara-VCD Consolidation and Daratumumab Maintenance in Newly Diagnosed AL Amyloidosis
NCT06022939Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2024
- Primary completion
- Jul 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Darzalex Faspro in amyloid light chain amyloidosis (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Major organ deterioration progression-free survival up to 4 years. Started Jul 2024; status: recruiting.
02
Drugs
Darzalex Faspro
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT06022939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022939.